USP Responding To Congress' Questions On Medicare Formulary Guidelines
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.S. Pharmacopeia has provided information to two congressional committees as it moves toward finalizing its model formulary guidelines for the Medicare drug benefit. USP emphasizes that no decision on the final structure of the guidelines has been made; final recommendations to CMS are expected by year-end.